The 2026 Annual Meeting of the American Association for Cancer Research (AACR) will be grandly held in San Diego, California from April 17 to 22, under the theme of "Precision, Collaboration, Mission." As the most influential top-tier academic event in global oncology, the AACR Annual Meeting is consistently committed to bridging basic research and clinical translation, driving revolutionary breakthroughs in cancer prevention, diagnosis, and treatment through multidisciplinary collaborative innovation, and serving as a barometer for pharmaceutical innovation and international cooperation. It is reported that over 30 cutting-edge studies from China will be selected for the highly anticipated oral presentation session, covering multiple frontier areas including ALK small-molecule targeted drugs, ADCs, bispecific/trispecific antibodies, and TCE.

Xuanzhu Biotech, as the flagship innovative drug subsidiary under China's leading pharmaceutical group Sihuan Pharmaceutical Group, specializes in multiple disease areas including oncology, gastroenterology, and metabolism. It is one of the few domestic innovative drug companies possessing comprehensive capabilities across the entire industrial chain for both large-and small-molecule drug development, production, and sales, along with fully independent intellectual property rights.

At this year's AACR Annual Meeting, Xuanzhu Biotech will showcase a series of groundbreaking achievements. Among them, its core product Dirozalkib has secured one oral presentation and one poster presentation. As a next-generation ALK inhibitor, Dirozalkib demonstrates exceptional efficacy and favorable safety profile in patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), making it highly anticipated. Another flagship product, Bireociclib, was also featured in one poster presentation. As the first CDK2/4/6 inhibitor approved for marketing in China, Bireociclib has consistently demonstrated significant clinical benefits in the treatment of HR+/HER2-negative advanced breast cancer. Both Dirozalkib and Bireociclib will be presented together at the 2026 AACR Annual Meeting, delivering outstanding presentations that are highly anticipated!

Please stay tuned for Xuanzhu Biology's oral presentation and poster exhibition.

About Xuanzhu Biology:

Xuanzhu Biotech (Stock Code: 02575.HK) is an innovative pharmaceutical company rooted in China with a global vision, focusing on major disease areas such as digestive disorders, oncology, and non-alcoholic fatty liver disease. The company is dedicated to the research, development, production, and commercialization of Class 1 new drugs with core independent intellectual property rights. It boasts a top-tier R&D team, with key members possessing extensive experience in new drug development. As a cutting-edge commercial innovator driven by R&D and empowered by AI, the company has established a rare product pipeline in China that encompasses various categories including small-molecule chemical drugs, large-molecule biologics, and antibody-drug conjugates (ADCs). The company operates guided by unmet clinical needs.